| Assessment Status | Rapid Review Complete |
| HTA ID | 26040 |
| Drug | Depemokimab |
| Brand | Exdensur® |
| Indication | Depemokimab (Exdensur®) is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. |
| Assessment Process | |
| Rapid review commissioned | 21/08/2026 |
| Rapid review completed | 09/09/2026 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of depemokimab for this indication compared with the current standard of care, on the basis of the proposed price relative to currently available therapies. |
Next steps: The NCPE Assessment Report and recommendation, will be considered by the HSE when making their decision on reimbursement, while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Further information on this process may be found here
Further information on the status of this decision may be found here